Kamada Ltd.

NasdaqGS:KMDA Stock Report

Market Cap: US$411.7m

Kamada Past Earnings Performance

Past criteria checks 3/6

Kamada has been growing earnings at an average annual rate of 39.6%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 11.3% per year. Kamada's return on equity is 7.9%, and it has net margins of 11.2%.

Key information

39.61%

Earnings growth rate

34.59%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate11.34%
Return on equity7.85%
Net Margin11.21%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Jun 02

Kamada: Undervalued, Yet Execution Risks Keep It A Hold

Summary Kamada Ltd. maintains solid demand and profitability, but near-term margin pressures and execution risks justify a hold rating. FDA approval of the in-house RFFIT lab removes a key operational bottleneck, supporting vertical integration and future growth in the rabies franchise. 1Q26 results showed stable revenues ($45.2M, +3% YoY) and a robust 26% EBITDA margin, offset by gross margin compression and shipment timing effects. KMDA trades at a discount to the sector on FWD EV/EBITDA (7.4x vs. 11.6x), but the market discounts margin sustainability and execution risks despite strong forward growth prospects. Read the full article on Seeking Alpha
Seeking Alpha • Oct 19

Kamada secures $22M extension of Canadian supply tender

Kamada (NASDAQ:KMDA) was awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG® and WINRHO® SDF, for an additional three years for an approximate total value of $22M. The award secures the ongoing sales of those products in the Canadian market. The four commercial products, approved by Health Canada and the U.S. Food and Drug Administration were acquired by Kamada in November 2021. CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec. The supply extension secures ongoing sales of approximately $7.5M per year for 2023-2025, with an option to extend for up to additional two years. Commercial manufacturing of CYTOGAM at Kamada’s Israeli manufacturing plant is expected to be initiated during 2023.
Seeking Alpha • Aug 16

Kamada Q2 2022 Earnings Preview

Kamada (NASDAQ:KMDA) is scheduled to announce Q2 earnings results on Wednesday, August 17th, before market open. The consensus EPS Estimate is -$0.02 (-200.0% Y/Y) and the consensus Revenue Estimate is $23.69M (-2.1% Y/Y). Over the last 1 year, KMDA has beaten EPS estimates 25% of the time and has beaten revenue estimates 25% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Revenue & Expenses Breakdown

How Kamada makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:KMDA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2618220418
31 Dec 25180204010
30 Sep 25175203711
30 Jun 25170193612
31 Mar 25167163614
31 Dec 24161143614
30 Sep 24158163514
30 Jun 24155153414
31 Mar 24150123313
31 Dec 2314383114
30 Sep 2315263212
30 Jun 2314633112
31 Mar 23132-23011
31 Dec 22129-22813
30 Sep 22115-102711
30 Jun 22106-122411
31 Mar 22107-72211
31 Dec 21104-2209
30 Sep 211044199
30 Jun 21116121910
31 Mar 21125151711
31 Dec 20133171712
30 Sep 20134211612
30 Jun 20132201612
31 Mar 20134231611
31 Dec 19127221611
30 Sep 19143351610
30 Jun 1912526159
31 Mar 1912426148
31 Dec 1811422148
30 Sep 1810211147
30 Jun 1811013158
31 Mar 1810912159
31 Dec 1710371510
30 Sep 1791-11511
30 Jun 1788-21512
31 Mar 1774-81412
31 Dec 1677-71413
30 Sep 1679-41612
30 Jun 1676-81513
31 Mar 1676-81512
31 Dec 1570-111512
30 Sep 1569-111411

Quality Earnings: KMDA has high quality earnings.

Growing Profit Margin: KMDA's current net profit margins (11.2%) are higher than last year (9.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KMDA's earnings have grown significantly by 39.6% per year over the past 5 years.

Accelerating Growth: KMDA's earnings growth over the past year (26.8%) is below its 5-year average (39.6% per year).

Earnings vs Industry: KMDA earnings growth over the past year (26.8%) did not outperform the Biotechs industry 54.5%.

Return on Equity

High ROE: KMDA's Return on Equity (7.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 00:36
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kamada Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
Andrew FeinH.C. Wainwright & Co.
Anthony PetroneJefferies LLC